Lexicon Pharmaceuticals, Inc.
LXRX
$1.12
-$0.03-2.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 106.09% | 47.73% | 32.14% | -28.28% | -18.98% |
| Total Depreciation and Amortization | 26.62% | 22.22% | -14.97% | -16.56% | -3.47% |
| Total Amortization of Deferred Charges | -23.43% | -22.44% | -35.11% | -34.95% | 92.31% |
| Total Other Non-Cash Items | 7,940.00% | -95.66% | -100.70% | 241.75% | -100.66% |
| Change in Net Operating Assets | 163.60% | -67.72% | 375.15% | 23.41% | 66.34% |
| Cash from Operations | 135.01% | 20.59% | 57.48% | -28.83% | -27.34% |
| Capital Expenditure | -- | -- | -- | -269.88% | -79.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 228.24% | 136.82% | 4.39% | 237.03% | 83.79% |
| Cash from Investing | 225.64% | 136.82% | 3.47% | 235.96% | 83.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | 66.94% | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -321,328.57% | -100.24% | -10,300.00% | -336.19% | -100.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 79.43% | -105.09% | 2,279.91% | 98.69% | -179.82% |